Increased dosage of tumor suppressors limits the tumorigenicity of iPS cells without affecting their pluripotency by Menendez, Sergio et al.
Increased dosage of tumor suppressors limits the
tumorigenicity of iPS cells without affecting
their pluripotency
Sergio Menendez,1 Suzanne Camus,1,* Aida Herreria,1,*
Ida Paramonov,1 Laura B. Morera,1 Manuel Collado,2
Vlad Pekarik,1 Iago Maceda,1 Michael Edel,1,3,† Antonella
Consiglio,1,4, Adriana Sanchez,1, Han Li,2 Manuel
Serrano2 and Juan C. I. Belmonte1,5
1Center for Regenerative Medicine in Barcelona, C ⁄Dr. Aiguarder 88,
Barcelona 08003, Spain
2Tumor Suppression Group, Spanish National Cancer Research Centre
(CNIO), 3 Melchor Fernandez Almagro Street, Madrid E-28029, Spain
3Honorary Research Fellow, Molecular Cardiology and Biophysics, Victor
Chang Cardiac Research Institute, Sydney, NSW 2010, Australia
4Department of Biomedical Science and Biotechnology, University of
Brescia, Viale Europa 11, 25123 Brescia, Italy
5Gene Expression Laboratory, Salk Institute for Biological Studies, 10010
North Torrey Pines Road, La Jolla, CA 92037, USA
Summary
Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells
represent a promising therapeutic tool for many diseases, includ-
ing aged tissues and organs at high risk of failure. However, the
intrinsic self-renewal and pluripotency of ES and iPS cells make
them tumorigenic, and hence, the risk of tumor development hin-
ders their clinical application. Here, we present a novel approach
to limit their tumorigenicity and increase their safety through
increased copy number of tumor suppressors. iPS containing an
extra copy of the p53 or Ink4a ⁄ARF locus show normal pluripoten-
cy, as determined by in vitro and in vivo differentiation assays.
Yet, while retaining full pluripotency, they also possess an
improved engagement of the p53 pathway during teratocarci-
noma formation, which leads to a reduced tumorigenic potential
in various in vitro and in vivo assays. Furthermore, they show an
improved response to anticancer drugs, which could aid in their
elimination in case tumors arise with no adverse effects on cell
function or aging. Our system provides a model for studying
tumor suppressor pathways during reprogramming, differentia-
tion, and cell therapy applications. This offers an improved under-
standing of the pathways involved in tumor growth from
engrafted pluripotent stem cells, which could facilitate the use of
ES and iPS cells in regenerative medicine.
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Introduction
The p53 tumor suppressor gene integrates the response of multiple
stress-activated pathways and plays a critical role in tumor prevention.
It is estimated that p53 is directly mutated or indirectly inactivated in
the majority of human tumors (Lane & Levine, 2010). Linked to the p53
pathway, the Ink4 ⁄ARF tumor suppressor locus encodes three impor-
tant tumor suppressors, p16Ink4a and p19ARF from Cdkn2a and
p15Ink4b from Cdkn2b. This locus therefore integrates two main antit-
umoral pathways, the p53 pathway, via the interaction of p19ARF with
the p53 inhibitor protein Mdm2, and the pRB pathway, via the inhibi-
tion of cyclin-D-dependent kinases CDK4 and CDK6 by p15Ink4b and
p16Ink4a (Collado & Serrano, 2006). The effect of activating these
pathways in tumor prevention ⁄ treatment strategies has therefore been
long studied.
However, little is known regarding the role of these tumor suppres-
sors in tumors arising from cell therapy techniques involving embryonic
stem (ES) and induced pluripotent stem (iPS) cells. Such techniques
hold the promise of revolutionizing the field of regenerative medicine
(Thomson et al., 1998; Takahashi et al., 2007), but the tumorigenic
risk of iPS and ES cell replacement therapies hinders their clinical appli-
cation (Blum & Benvenisty, 2008; Belmonte et al., 2009; Kiuru et al.,
2009). Pluripotent stem cells generate benign teratomas or more
aggressive teratocarcinomas upon engraftment in vivo (Ben-David &
Benvenisty, 2011), with as few as 20 undifferentiated cells being able
to generate a tumor (Lawrenz et al., 2004). In addition, other sources
of pluripotent or multipotent cells such as mesenchymal stem cells
(MSC) or cord blood stem cells can also drive tumor formation upon
engraftment in vivo in human patients after cell therapy (Ando et al.,
2006; Greaves, 2006). We hypothesized that the p53 pathway may be
engaged during teratoma formation and that taking advantage of the
endogenous pathways that prevent tumorigenesis could provide an
attractive approach to limit the tumorigenicity of pluripotent stem
cells.
However, p53 is linked to many cell processes, including metabolism
and aging. The constitutive activation of p53, in fact, has been linked to a
premature aging phenotype (Tyner et al., 2002). As stress-induced activa-
tion of p53 leads to cell senescence, it is logical that prolonged activation
of p53 would affect organismal aging. We have recently described iPS cell
models that offer a relevant system to study both physiological and path-
ological aging (Liu et al., 2011), highlighting the utility of iPS systems to
model these processes.
Here, we present an iPS model system in which we employ increased
dosage of the tumor suppressors p53 and the InK4a locus to investigate
the pathways involved in teratoma formation from ES and iPS cells used
in cell therapy applications. Our models could prove useful for studying
the involvement of these tumor suppressor pathways in organismal
aging and aging-related pathologies. We demonstrate that increased
dosage of these tumor suppressors leads to a reduced tumorigenic
potential and an increased therapeutic index, in the event of tumors
arising, without any apparent adverse effects on normal cell function or
aging.
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Results
iPS derivation and characterization
We employed iPS cells derived from mouse embryonic fibroblasts (MEFs)
harboring an extra copy of either the p53 tumor suppressor gene (p53
super mice) (Garcia-Cao et al., 2002) or the Ink4a ⁄ARF tumor suppressor
locus (Ink4a ⁄ARF super mice) (Matheu et al., 2004) to investigate the
effect of increased tumor suppressor dose on the tumorigenic potential
of pluripotent cells. Initially, we reprogrammed passage-one MEFs
derived from p53 super mice (p53 iPS), Ink4a ⁄ARF super mice (Ink4a ⁄ARF
iPS), or the parental wild-type control (wt iPS). Three individual iPS clones
from each cell type were selected by morphological criteria and charac-
terized by immunostaining for the pluripotency markers Oct4, Sox2, Na-
nog, and SSEA1 (Figs 1a and S1). Quantitative PCR analysis confirmed
that total levels of c-Myc, Klf4, Oct4, and Nanog mRNA were comparable
to the control ES cell line (Fig. S2), indicating pluripotency and silencing
of the transgenes in the lines tested. All iPS lines could differentiate to the
three germ layers in vitro (Fig. S3) and in vivo (Figs 1b and S4) and had
normal karyotypes (Fig. S5). Furthermore, p53 and Ink4a ⁄ARF iPS cells
could contribute to chimera formation when injected into mouse blast-
ocysts, with a success rate at least as high as that of the wt iPS cell con-
trols in every attempt (five representative chimeric pups per condition are
shown in Fig. 1c). Finally, wt, p53, and Ink4a ⁄ARF iPS can all support
germ-line transmission (Fig. 1d). These results confirm the bona fide plu-
ripotent nature of the iPS generated from MEFs harboring an extra copy
of p53 or Ink4a ⁄ARF. In addition, the cell cycle profile and growth rate
(Fig. 1e,f) of wt, p53, or Ink4a ⁄ARF iPS cell lines are equivalent under nor-
mal growth conditions, indicating that the tumor suppressors are not
constitutively active in the absence of stress signaling and that the pres-
ence of the extra copy of the p53 or Ink4a ⁄ARF locus has little influence
on the iPS cells behavior under nonstressed conditions. These data are as
expected from mouse models as the tumor suppressors are subject to the
normal regulatory controls and do not show increased levels or activity
under nonstressed conditions (Garcia-Cao et al., 2002; Matheu et al.,
2004).
We further analyzed our wt, p53, and Ink4a ⁄ARF iPS cell lines and com-
pared them with three ES cell lines of the same genetic background using
an expression profile array. As expected, all iPS cell lines have highly simi-
lar expression profiles with each other and with ES cells (Pearson correla-
tion coefficient higher than 0.99 for all comparisons, see Figs 2a,b and
S6), further confirming their bona fide pluripotent nature. From this anal-
ysis, we also observed that the differences in the expression profiles
between wt, p53, and Ink4a ⁄ARF iPS cell lines were comparable with the
differences observed between different clones of iPS cells of the same
type (shown for three different clones of wt iPS cells and one clone of wt,
p53, and Ink4a ⁄ARF iPS cells, see Fig. 2c). This indicates that under nor-
mal growth conditions the presence of one extra tumor suppressor copy
has little impact on the iPS cells expression profile. These data also show
that the presence of an extra copy of the p53 or Ink4a ⁄ARF locus prior
(A) (C)
(D)
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Fig. 1 wt, p53, and Ink4a ⁄ ARF induced pluripotent stem (iPS) cells show equivalent pluripotency and chimera contribution efficiency (a) wt, p53, or Ink4a ⁄ ARF iPS cell
colonies grown over a mouse embryonic fibroblast (MEFs) feeder layer were stained with antibodies (Ab) against Sox2 or Oct4 as indicated. (b) wt (not shown), p53, and Ink4a
iPS cells were injected intramuscularly in NOD-SCID mice (1 · 106 cells per injection). Resulting teratomas were removed when they reached an appropriate size and then
fixed and analyzed by immunohistochemistry with Ab against Tuj1 (green) and GFAP (red), aFP (green) and FOXA2 (red), aSMA (green) and aSA (red) as indicated to
demonstrate differentiation to the relevant germ layers. (c) wt, p53, and Ink4a ⁄ ARF iPS cells (C57BL ⁄ 6J background, black coat color) were injected into 3.5-dpc blastocyst of
B6(cg)-Tyrc-2J ⁄ J mice (abbreviated Tyr, white coat color) and then transferred into pseudo-pregnant Tyr recipients for chimera generation. Five representative chimeras
derived from wt, p53, or Ink4a ⁄ ARF iPS cells are shown. (d) Transgenic mice derived from wt, p53, or Ink4a ⁄ ARF iPS cells are shown together with a Tyr wt control mouse.
(e) FACs analysis of the cell cycle profile or (f) growth curve quantification of undifferentiated wt, p53, and Ink4a ⁄ ARF iPS cells grown in culture under nonstressed conditions
show that there is no significant difference in their proliferation rate.
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Fig. 2 Mutation rate is not affected by increased tumor suppressor dosage. (a) Pearson correlation coefficients of the averaged expression profiles of three independent
embryonic stem (ES) clones, three independent p53 induced pluripotent stem (iPS) clones, two independent Ink4a ⁄ ARF iPS clones, and three independent wt iPS clones
(shown individually to highlight clonal variation among equivalent samples) are shown. (b) Scatter plots of global gene expression profiles of the average of ES versus the
average of wt, p53, and Ink4a ⁄ ARF iPS cells are shown. (c) Venn diagrams showing the number of differentially expressed genes between the average of ES and the average
of wt, p53, and Ink4a ⁄ ARF iPS cells (left) or three independent wt iPS cells (right) are shown. (d) Chromosomal location enrichment analysis of three independent ES cells
clones and one clone of wt, p53, and Ink4a ⁄ ARF iPS cells that was used in all experiments performed throughout the manuscript unless otherwise stated is shown. P-values
<0.0001 are highlighted in green. (e) Hierarchical clustering of ES and iPS samples described in (d) based on real-time RT-PCR data. Scale bar shows log2-transformed ratio
values.
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and during the process of reprogramming has no effect on the final
expression profile of iPS cells.
Mutation rate is not affected by increased tumor suppressor
dosage
Mutations accumulate during the reprogramming process in at least a
proportion of iPS cell lines (Mayshar et al., 2010; Gore et al., 2011;
Hussein et al., 2011). Because p53 protects proliferating cells from the
accumulation of mutations, it is possible that an increased copy number
could limit the accumulation of mutations during reprogramming. Our
direct analysis of the expression profile array data suggests that this is not
the case in the clones that we have analyzed (three wt-, three p53-, and
two Ink4a ⁄ARF-independent iPS cell clones). However, to further explore
this possibility, we mined our expression profile array data to look for
large duplications or deletions accumulated during reprogramming. A
similar approach has already been validated and has a sensitivity range
capable of identifying duplications or deletions from 10 kb in size (May-
shar et al., 2010). We did not identify any highly significant overrepre-
sentation of overexpressed or underexpressed genes in our wt, p53, or
Ink4a ⁄ARF iPS cell lines or in our control ES cell lines (Fig. 2d), indicating
that there were no detectable large duplications or deletions in our iPS
or ES lines. The differences observed between our wt, p53, or Ink4a ⁄ARF
iPS cell lines were at the level that could be expected from clonal varia-
tion, as quantitatively similar variations were observed among the three
ES lines used as a control (Fig. 2d). As the mutational changes reported
to accumulate during reprogramming are biased toward loss of tumor
suppressor and ⁄ or gain of oncogenes (Gore et al., 2011; Hussein et al.,
2011), to further validate our conclusions, we designed a ‘focused array’
based on tumor suppressors, oncogenes, and genes involved in various
aspects of cancer such as metastasis, intercellular interactions, and trans-
duction signaling. We then performed quantitative real-time PCR analy-
sis to measure mRNA expression for this gene set in our wt, p53, or
Ink4a ⁄ARF iPS cell lines using three clones of ES cells as a baseline
(Figs 2e and S7). In agreement with our mRNA array data, we did not
observe any differences in mRNA expression between our wt, p53, or
Ink4a ⁄ARF iPS cell lines beyond the clonal variation seen among our ref-
erence ES cell lines, further confirming that the presence of the tumor
suppressor transgenes during reprogramming did not alter the iPS cell
lines obtained.
Increased p53 or Ink4a ⁄ARF dosage reduces the tumorigenic
potential of iPS cells
We then tested the effect of increased p53 or Ink4a ⁄ARF copy number
on the tumorigenic potential of iPS cells. Firstly, we performed soft agar
growth assays, which are a standard test of tumorigenicity that reflects
the capacity of a cell to grow in conditions of low nutrients and low oxy-
gen and in an anchorage-independent manner. A marked reduction in
the growth of p53 and Ink4a ⁄ARF iPS cells was observed compared with
the wt control for several independent iPS clones, indicating that the
tumorigenic potential of p53 and Ink4a iPS is reduced compared with wt
cells and that this is independent of differences caused by retroviral
insertion (Fig. 3a). To study the tumorigenic potential of engrafted iPS
cells in vivo, we performed long-term and short-term teratoma assays
(see Data S1). These assays are not a measurement of the pluripotency of
the iPS cells (which has already been demonstrated in Figs 1 and S1–S4)
as the cells were injected under ‘nonsaturating’ conditions (as detailed in
Data S1) and are therefore informative in relation to the comparative effi-
ciency with which the different cell lines can give rise to tumors. In long-
term teratoma formation assays, in which animals were sacrificed
depending on stringent predefined health parameters (see Experimental
procedures), a substantial reduction in teratoma formation in mice
injected with p53 and Ink4a ⁄ARF iPS was observed compared with wt iPS
(Fig. 3b,c). Interestingly, some Ink4a ⁄ARF iPS-injected mice failed to
develop any teratomas for the entire duration of the assay (Figs 3b and
S8). In agreement, in short-term teratoma assays, in which the end point
was predetermined, a decrease in tumor size and weight was observed
for p53 iPS- and Ink4a ⁄ARF iPS- compared with wt iPS-injected mice.
Again, p53 iPS- and Ink4a ⁄ARF iPS-injected individuals were observed
that failed to develop teratomas throughout the duration of the assay,
whereas teratomas were formed in all wt-injected animals (Figs 3d,e and
S9). Importantly, we observed a clear decrease in the proliferation rate of
p53 iPS- and Ink4a ⁄ARF iPS-derived teratomas compared with the wt
control (Fig. 3e). This is in stark contrast to undifferentiated iPS in non-
stressed culture conditions, where there was no difference in the prolifer-
ation rate between wt, p53, and Ink4a ⁄ARF cells (Fig. 1e,f). We did not
observe an increase in the apoptotic rate in these tumors (data not
shown), suggesting that limited proliferation was a major cause for the
reduction in tumor size and number in p53 iPS- and Ink4a ⁄ARF iPS-
derived teratomas. Tumors derived from injection of mouse iPS in immu-
nocompromised mice have been shown to contain a malignant undiffer-
entiated population of embryonic carcinoma (EC) cells and, therefore,
should be categorized as teratocarcinomas (Blum et al., 2009). This EC
cell component is positive for the EC markers Oct4 and Nanog and is
responsible for the proliferation of the tumor and its capability to form
secondary teratomas (Blum & Benvenisty, 2008). When the EC compart-
ment of our teratomas was analyzed, we observed a marked decrease in
the percentage of Oct4-positive cells in the p53- and Ink4a ⁄ARF-derived
teratocarcinomas (Figs 3f and S10). By dissociation of the teratocarcino-
mas, we isolated EC cells that could be passaged in vitro. As expected, we
obtained a higher proportion of EC cells from wt iPS-derived teratocarci-
nomas than from p53 iPS- or Ink4a ⁄ARF iPS-derived teratocarcinomas
(Fig. 3g). Together, these results demonstrate that p53 and Ink4a ⁄ARF
iPS have decreased tumorigenicity compared with wt iPS in a range of
established in vitro and in vivo assays.
Increased tumor suppressor dosage reduces the tumorigenic
potential of differentiated iPS cells
We next studied the tumorigenic potential of the p53 and Ink4a ⁄ARF iPS
in an in vivo context relevant for cell therapy. In this regard, we differenti-
ated iPS lines into skeletal muscle (Mizuno et al., 2010) (Fig. 4a,b), a ther-
apeutically relevant cell type that can be used in the treatment for
muscular dystrophies (Darabi et al., 2008), and injected them into the
skeletal muscle tissue of NOD-SCID mice. We injected a nonpurified pop-
ulation of differentiated cells for all three cells types. These populations
did not contain Oct4- or Nanog-positive cells at the detection level
achieved by FACs analysis (data not shown); however, a small amount of
Nanog and Oct4 mRNA was still detectable in the samples by quantitative
real-time PCR (data not shown), indicating that some undifferentiated
cells still remained in the injected sample. Teratocarcinomas arose in all of
the wt iPS cell-injected mice; however fewer and, when present, smaller
tumors were observed in both the p53 iPS- and Ink4a ⁄ARF iPS-injected lit-
termates, indicating that the increased dosage of p53 or Ink4a ⁄ARF offers
substantial protection against teratocarcinoma formation in this system
(Fig. 4c). Importantly, we detected a differential induction of the p53,
p21Cip1, p19ARF, and p16INK4a proteins in teratocarcinomas derived
from p53 and INK4a ⁄ARF iPS cells compared with wt iPS-derived terato-
carcinomas (Figs 4d and S11). This demonstrates a more effective
Safer iPS by enhancement of tumor suppressors, S. Menendez et al.
ª 2011 The Authors
Aging Cell ª 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland
44
(A)
(C)
(B)
(D)
(F)
(E)
(G)
Fig. 3 Increased p53 or Ink4a ⁄ ARF dosage reduces the tumorigenic potential of induced pluripotent stem (iPS) cells. (a) Soft agar colony formation assays were performed
with three different clones of wt, p53, or Ink4a ⁄ ARF iPS cells. Cells were grown for approximately 2 weeks, fixed, and stained, and the total number of colonies was
quantified. The colony formation efficiency corresponding to each clone was calculated by dividing the total number of colonies by the initial number of cells seeded. The
relative colony formation efficiency of the different clones was then calculated against that of the wt iPS cells and plotted as shown. (b) Long-term teratoma formation assay.
wt, p53, or Ink4a ⁄ ARF iPS cells were injected intramuscularly and subcutaneously (1 · 105 cells per injection point, and one intramuscular and one subcutaneous injection
point per animal) in NOD-SCID mice. Animals were sacrificed after tumor formation following stringent predetermined parameters (see Data S1) at a time advised by a
specialized veterinarian. Teratomas formed were measured and fixed for further analysis at the point of sacrifice. The day of sacrifice, teratoma presence (h = subcutaneous,
s = intramuscular), and grade (+++ 2 cm teratoma, ++ 1–2 cm teratoma, + teratoma smaller than 1 cm, and – no teratoma) are plotted. T = the number of teratomas
formed out of the total number injected. A Student t-test statistical analysis was performed on the total teratoma number for p53 or Ink4a ⁄ ARF iPS versus the wt iPS-injected
animals. P-values are indicated. (c) Table summarizes the results from b. The mean sacrifice day and the mean actual and relative (as compared with the wt control) tumor
grade for the subcutaneous and intramuscular tumors derived from injection of wt, p53, or Ink4a ⁄ ARF iPS cells are represented. Mean tumor grade was calculated assigning
an arbitrary value of three to 2-cm tumors (+++), two to 1- to 2-cm tumors (++), one to tumors smaller than 1 cm (+) and zero to absence of tumor ()). (d) Short-term
teratoma experiment. wt, p53, or Ink4a ⁄ ARF iPS cells were injected intramuscularly and subcutaneously (1 · 105 cells per injection point) in NOD-SCID mice. Four weeks after
injection, mice were sacrificed and the resulting teratomas were extracted and weighed. The mean intramuscular teratoma weight is represented relative to the wt. Statistical
analysis was performed as in b. (e) Proliferation analysis of the wt-, p53-, or Ink4a ⁄ ARF iPS-derived teratomas. After extraction, teratomas were fixed, sectioned, and stained
with Ab against the proliferation markers PCNA, Ki67, and phospho-histone H3 (Phh3). Sections from the whole length of each teratoma were stained and quantified using
MetaMorph software. Percentage of positive cells for each marker is represented as shown. (f) Graph shows the percentage of Oct4-positive cells present in teratomas from
wt-, p53- and Ink4a ⁄ ARF iPS-injected mice, as indicated. At least three sections of two independent teratomas per condition were quantified. Statistical analysis was
performed as in b. (g) wt-, p53-, or Ink4a ⁄ ARF-derived teratomas were extracted, disaggregated to a single-cell suspension. The cells were counted, then plated on slide
flasks, and stained for the embryonic carcinoma cell markers Oct4 and Nanog. Double positive colonies after seeding of 1 · 105 cells were quantified and plotted for each
condition.
Safer iPS by enhancement of tumor suppressors, S. Menendez et al.
ª 2011 The Authors
Aging Cell ª 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland
45
(A) (B)
(D)
(C)
(F)
(E)
(G)
Fig. 4 Increased tumor suppressor dosage reduces the tumorigenic potential of differentiated induced pluripotent stem (iPS) cells. (a) Bright-field images of p53 and
Ink4a ⁄ ARF iPS differentiated to skeletal muscle. Arrowheads identify individual muscle fibers at 10· and 20· magnification. (b) Reverse transcription PCR for the skeletal
muscle markers Pax3, MyoD, and Myogenin in undifferentiated iPS and iPS differentiated to skeletal muscle. (c) Graph showing the weight of each individual teratoma and
the overall mean teratoma weight from wt, p53, and Ink4a ⁄ ARF skeletal muscle differentiated cells injected intramuscularly in the gastrocnemius of NOD-SCID mice. A
Student t-test statistical analysis was performed for p53 or Ink4a ⁄ ARF iPS versus the wt iPS, and P-values are indicated. (d) Analysis of the proportion of p19ARF-, p53-,
p21Cip1, and p16Ink4-positive cells present in teratomas from wt-, p53-, and Ink4a ⁄ ARF iPS-injected mice, as indicated. At least three sections of three independent
teratomas per condition were analyzed. One representative section is shown per condition. For further images, please see Fig. S10. (e) Generation of functional neurospheres
(NS) from wt and p53 iPS. Bright-field image of primary NS and staining of primary NS differentiated on laminin with the neuronal marker Tuj1, the astrocyte marker GFAP,
and the oligodendricyte marker CNPase as indicated. (f) Images from the engraftment area (p53) or teratomas (wt) originating from injection of disaggregated primary NS
into the right striatum of NOD-SCID mice (5 · 105 cells per injection point). iPS cells were labeled with GFP using lentiviral infection prior to the differentiation in order to be
able to track cell engraftment in vivo. A representative example of one of the teratomas generated from wt iPS positive for the endodermal marker FOXA2 and the
mesodermal marker SMA is shown as indicated. A representative example of engrafted cells from p53 iPS NS positive for the neuronal lineage markers Tuj1 and GFAP and
negative for endodermal or ectodermal markers is shown as indicated. (g) Quantification of the teratomas arising from wt iPS NS or p53 iPS NS under our experimental
conditions. Statistical analysis was performed as in c.
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engagement of the p53 and INK4a ⁄ARF pathways in the p53 iPS- and
INK4a ⁄ARF iPS-derived teratocarcinomas and agrees with the reduced
proliferation observed in these teratocarcinomas (Fig. 4c). Furthermore,
there was no significant difference in the induction of differentiation
markers or reduction in pluripotency markers between wt, p53, and
INK4a ⁄ARF iPS cells upon differentiation, either in general nonlineage-
directed differentiation protocols or in specific differentiation to skeletal
muscle (Figs S12 and 4b). This supports a direct role of the differential
activation of p53 and INK4a ⁄ARF in limiting teratocarcinoma formation
and proliferation in vivo.
To further study the effect of increased dosage of p53 in an additional
in vivo context relevant for cell therapy, we performed differentiation to
primary neurospheres (NS) (Fig. 4e) and injected the disaggregated NS
into the striatum of NOD-SCID mice, an assay previously used to quantify
tumorigenicity in iPS cells (Miura et al., 2009). In this assay, the engrafted
cells are still not terminally differentiated progenitor cells. Therefore, they
still retain some multipotency and can be differentiated into three differ-
ent cell types: astrocytes, oligodendrocytes, and neurons. In this context,
we observed a significant reduction in the formation of teratomas in p53
cells compared with wt cells with a similar engraftment level for both cell
types (Fig. 4f,g), while the p53 iPS cells retain an intact capacity to differ-
entiate into neuronal cells (as determined by positive Tuj1 staining,
Fig. 4f), highlighting in an additional in vivo differentiation context their
bona fide pluripotent nature. These results further indicate that the p53
(A) (B)
(C) (D)
(E) (F)
Fig. 5 Transgenic mice derived from p53 induced pluripotent stem (iPS) cells show reduced tumor formation and no aging phenotype. (a) wt, p53, and Ink4a ⁄ ARF iPS cells
were treated with the antitumoral drugs nutlin-3 (2 lM final concentration), R-roscovitine (2 lM), mitomycinC (1 lg ml)1), or leptomycin B (0.2 nM) for 48 h and then fixed,
stained, and quantified. A quantification of the cell number in the presence of each drug relative to the untreated control is shown. (b) The cell cycle profile of wt, p53, and
Ink4a ⁄ ARF iPS drugged overnight with nutlin-3 (N), roscovitine (R), and leptomycin B (LB) was analyzed by FACs. The percentage of cells in the G1, S, and G2 ⁄ M phases of cell
cycle for the treated and untreated control cells was quantified. (c) Cells derived from wt, p53, and Ink4a ⁄ ARF iPS teratomas were isolated and grown in culture. Embryonic
carcinoma (EC) cell colonies were identified by double staining with Ab against Nanog and Oct4, as indicated. (d) EC cells were treated with the antitumoral drugs nutlin-3,
roscovitine (Rosc, 2 lM), or two concentrations of leptomycin B (LB high, 0.4 nM and LB low, 0.2 nM) and quantified as in (a). (e) iPS cells were treated with the antitumoral drugs
roscovitine (low, 2 lM or high, 4 lM) or leptomycin B (LB high 0.4 nM; LB medium 0.2 nM; and LB low 0.1 nM) for 24 h. p53 levels were analyzed by western blot in wt, p53, or
INK4a ⁄ ARF iPS cells as indicated. Actin levels are shown as an internal control. (f) iPS cells were placed under normal growth conditions or under hypoxia (1% oxygen) and low
nutrients (1% FCS) conditions for 16 h. p53 levels were analyzed by western blot in wt, p53, or INK4a ⁄ ARF iPS cells as indicated. Actin levels are shown as an internal control.
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pathway is engaged in a wide range of cellular contexts during teratoma
formation and that the protective effect against tumor formation
obtained by increasing p53 copy number is valid for a range of differenti-
ation strategies for cell therapy.
Increased dosage of tumor suppressors offers an improved
therapeutic index
Because the p53 and pRB pathways are two of the main pathways
engaged during the antiproliferative response elicited by antitumoral
drugs (Vazquez et al., 2008; Brown et al., 2009), we next investigated
whether the extra copy of p53 or Ink4a ⁄ARF confers an improved thera-
peutic index. We therefore treated wt, p53, and Ink4a ⁄ARF iPS cells with
a panel of antitumoral drugs, including drugs currently used therapeuti-
cally or undergoing clinical trials. Using a lower concentration than nor-
mally administered, we observed a strong antiproliferative effect upon
treatment of p53 and, especially, Ink4a ⁄ARF iPS cells, whereas little or no
reduction in proliferation was observed in wt iPS cells (Fig. 5a). As drugs
that have no effect on DNA integrity are more suitable candidates for
chemotherapy, we studied the effect of such drugs on the cell cycle pro-
file of our iPS cell lines. As expected, these drugs have a more profound
effect on the cell cycle profile of p53 and Ink4a ⁄ARF iPS cells than on wt
control cells, inducing a significant arrest in G1 and G2 ⁄M in short-term
assays (Fig. 5b), which correlates with the antiproliferative effect elicited
in colony formation assays (Fig. 5a). These results also demonstrate in an
in vitro context that a differential activation of the p53 pathway occurs in
iPS with increased tumor suppressor dosage under a wide range of stress
signaling conditions, ranging from DNA damage to nuclear export inhibi-
tion. This is in clear contrast to the behavior of p53 and Ink4a ⁄ARF iPS
cells under nonstressed conditions, which is undistinguishable from the
wt control iPS cells (see Figs 1 and 2).
Furthermore, these results were recapitulated by treatment of EC cell
lines (characterized by Nanog and Oct4 double staining, Fig. 5c) derived
from the teratocarcinomas generated from injection of our iPS cell lines
(Fig. 5d). In agreement with this, we observed a differential induction of
the p53 protein and of p53 target genes (Figs 5e and S13) upon drug treat-
ment in p53 and INK4a ⁄ARF iPS cells versus wt iPS cells, supporting that a
more effective engagement of the p53 pathway in p53 and INK4a ⁄ARF iPS
cells is responsible for the improved therapeutic index observed in these
cells. In addition, treatment with low concentrations of these antitumoral
drugs could specifically target tumor cells arising from cell therapy using iPS
cells that contain an extra copy of the p53 and Ink4a ⁄ARF genes. There-
fore, increased p53 and Ink4a ⁄ARF dosage could offer a substantially
improved therapeutic index in this tumor type, potentially limiting side
effects of the chemotherapy and allowing for a more specific targeting of
the tumor cell population. Finally, we observed a differential induction of
the p53 protein upon low nutrient and hypoxia conditions in p53 and
INK4a ⁄ARF iPS cells versus wt iPS cells in vitro (Fig. 5f), providing evidence
that low-nutrient and hypoxia-mediated stress pathways could drive the
differential activation of the p53 and INK4a pathways, decreased growth
rate and decreased EC cell compartment observed in p53 iPS- and
INK4a ⁄ARF iPS-derived teratocarcinomas compared with wt iPS-derived
teratocarcinomas in all conditions studied (Figs 3 and 4).
Transgenic mice derived from p53 iPS cells show reduced
tumor formation and no aging phenotype
The tumorigenicity of iPS cells has also been studied in the context of clas-
sical tumor development in transgenic animals generated from iPS. In this
context, tumor formation is triggered by reactivation of the transgenes
used for reprogramming (Okita et al., 2007). These studies provide inter-
esting information regarding the stability of transgene silencing upon
germ-line transmission induced modifications and have been widely used
to score the tumorigenicity of iPS cells. In this line, we have generated a
significant number of transgenic mice (approximately 100 mice per condi-
tion, aged between 4 and 12 months) from our p53 and wt iPS cells lines
to study the effect of the increased tumor suppressor copy number on
tumor development in this context. According to previous reports (Okita
et al., 2007; Nakagawa et al., 2010), iPS-derived mice developed tumors
owing to c-myc reactivation within a time frame of 2–10 months from
birth. We observed tumors arising in wt iPS-derived mice with a 5% inci-
dence owing to c-Myc reactivation, whereas no tumors have arisen in the
p53 iPS-derived transgenic mice (Fig. S14 and data not shown). These
results suggest that transgenic mice containing an extra copy of the p53
locus are resistant to tumor development because of c-myc reactivation.
No other health changes or abnormal aging phenotypes were observed in
our p53 iPS-derived transgenic mouse colony compared with their wt
counterparts.
Discussion
Here, we have employed standard assays used to analyze tumorigenicity,
such as soft agar assays and teratoma formation assays, as well as assays
that analyze the tumorigenicity of our iPS cells in an in vivo context rele-
vant for cell therapy, mimicking the conditions that are encountered in
such applications, namely the engraftment of progenitors or terminally
differentiated cells in a relevant tissue. Importantly, we demonstrate a sig-
nificant reduction in tumorigenicity of p53 and INK4a ⁄ARF iPS cells versus
wt iPS cells in all the different conditions studied, without affecting their
intrinsic properties under nonstressed growth conditions.
Interestingly, there were no adverse health effects in transgenic mice
derived from p53 iPS cells and no observation of phenotypes associated
with premature aging. This is in line with the lack of constitutive activa-
tion of the tumor suppressors in p53 compared with wt iPS cells, which
correlates with the fact that the increased tumor suppressor dosage
caused no effect on cell cycle proliferation under nonstressed conditions.
These data clearly indicate that an increased dosage of tumor suppressors
that are subject to endogenous regulatory mechanisms causes no adverse
effects under normal cellular conditions, despite being efficiently acti-
vated upon stress signaling.
The ability of pluripotent cells to generate teratomas does not depend
on genetic transformation, and thus, teratoma growth is driven by an
undifferentiated cell pool that retains a high proliferative rate and some
degree of pluripotency (Blum & Benvenisty, 2009). However, like other
tumors, their growth is still limited by oxygen and nutrient supply. Terato-
mas undergo an angiogenic switch that includes differentiation of plurip-
otent cells within the teratoma to form vessels (Li et al., 2009). However,
before this vascularization is achieved areas within the teratoma are
under hypoxia conditions. Given the profound effect that the increased
dosage of the p53 and Ink4a ⁄ARF locus had on the capability of iPS cells
to form colonies in soft agar assays, it is likely that hypoxia- and low-nutri-
ent stress-mediated signaling activates the p53 pathway during teratoma
formation to limit growth. In agreement, hypoxia directly activates the
p53 pathway (Graeber et al., 1996), and a clear link between p53 and
metabolism in cancer cells has recently emerged (Maddocks & Vousden,
2011). We further provide preliminary evidence of p53 activation in iPS
cells upon hypoxia and low nutrient supply (Fig. 5f). However, other
stress signaling pathways may also be involved in the activation of p53
during teratoma formation. In this regard, it is worth noting that DNA
damage also effectively triggers the activation of p53 in ES (Menendez
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et al., 2011) and iPS cells (Fig. 5a). In agreement with this observation,
increased tumor suppressor dosage facilitates the elimination of EC cells
at suboptimal concentrations of genotoxic and nongenotoxic antitumoral
drugs, offering an improved therapeutic index allowing specific targeting
of tumor cells with fewer expected side effects (Fig. 5).
Genetic modification of ES or iPS cells is an attractive methodology
to limit their tumorigenicity, as manipulation of their genome can be
easily achieved (Ellis et al., 2010). Therefore, increasing the dosage of
tumor suppressors could potentially be a suitable approach to limit the
tumorigenicity of ES or iPS cells in a clinical context. This approach pre-
sents advantages over the elimination of tumor cells that may arise
post-therapy or the selection of completely pure differentiated popula-
tions of cells for use in cells therapy (Ben-David & Benvenisty, 2011). It
could be of particular interest when undifferentiated progenitor cells
must be used for cell therapy or for iPS generated for the treatment
for diseases that require genetic correction and, therefore, genetic
manipulation of the host genome prior to cell therapy, especially if
these diseases carry an intrinsic risk of genomic abnormalities (Raya
et al., 2009). Further optimization of the tumor suppressor transgenes
used in this study remains needed owing to their large size, which hin-
ders their use for effective gene targeting into ES and iPS cells. The
design and optimization of a ‘minimal tumor suppressor cassette’
would therefore be required before this technology could be applied in
a clinical context.
Importantly, our model provides insight into the pathways involved in
the formation of teratomas from pluripotent cell sources used therapeuti-
cally. It further provides validation of the usefulness of iPS as a tool for
studying tumor suppressor pathways during cell reprogramming, differ-
entiation, and cell therapy applications, which are relevant for many con-
texts including tumor biology, aging, stress-activated pathways, and
metabolism.
Experimental procedures
Induced pluripotent stem were generated using the four original Yama-
naka pMXs retroviral vectors as described elsewhere (Kawamura et al.,
2009). The same clones of wt, p53, and Ink4a ⁄ARF iPS cells were used
in all experiments described in the manuscript unless otherwise stated.
Embryonic stem and iPS cells were used between passages 6–10. Im-
munostaining of iPS colonies, teratomas and quantification of staining
were performed as described elsewhere (Kawamura et al., 2009) and in
Data S1. Teratoma formation assays were performed following stan-
dard procedures, using a lower cell number for injection (1 · 105 iPS
cells per subcutaneous or intramuscular injection point unless otherwise
stated). Real-time PCR, RT-PCR, FACS analysis, soft agar assays, drug
treatments, cell quantification, and EC cell isolation from disaggregated
teratomas were also performed according to standard procedures; dif-
ferentiation to skeletal muscle (Mizuno et al., 2010), primary neuro-
spheres (Miura et al., 2009), and general differentiation protocols was
optimized from published protocols. For expression profile analysis, the
samples were hybridized to the Agilent SurePrint G3 Mouse Gene
Expression 8 · 60K Microarray, following standard procedures at the
Center Regulation Genomica Barcelona array facility. Microarray analy-
sis was performed following standard protocols, and detail information
can be found in the Data S1. Hierarchical clustering of qRT-PCR samples
was performed on log2-transformed ratio values using correlation met-
ric and the average linkage method with Cluster software and visual-
ized by TreeView software (Eisen et al., 1998). Mouse husbandry and
care followed standard procedures. Further details of all protocols can
be found in the Data S1.
Acknowledgments
We are grateful to the CMRB Histology and Bioimaging, Flow
Cytometry, Cell Culture, and Embryo Micromanipulation platforms.
We would also like to thank Ignasi Rodrı´guez-Piza` for sharing exper-
tise for teratoma formation assays and Stephanie Boue for helpful
discussions. A.C was supported in part by the Programa Ramon y
Cajal from the MICINN. Additional support was provided by grants
from MICINN (BFU2010-21823 to A.C), and Fondazione Guido Ber-
lucchi 2010 to A.C. Work in the laboratory of J.C.I.B was supported
by grants from MICINN, Tercel, G. Harold and Leila Y. Mathers Chari-
table Foundation, The Leona M. and Harry B. Helmsley Charitable
Trust, and Fundacion Cellex.
Author contributions
SM designed and performed experiments and wrote the manuscript.
SC performed experiments and wrote the manuscript. AH performed
experiments and help to design and monitor the in vivo experiments.
IB performed bioinformatics analysis. LBM generated the chimeras
and transgenic mice. IM performed quantitative PCR experiments.
MJE performed soft agar assays. VP, AC, and AS helped with the
neurosphere differentiation and injection protocol. HL and MC per-
formed reprogramming and histological analysis. MS provided
reagents and guidance. J.C.I.B provided direction and guidance for
the various aspects of the project.
References
Ando T, Yujiri T, Mitani N, Takeuchi H, Nomiyama J, Suguchi M, Matsubara A,
Tanizawa Y (2006) Donor cell-derived acute myeloid leukemia after unrelated
umbilical cord blood transplantation. Leukemia 20, 744–745.
Belmonte JC, Ellis J, Hochedlinger K, Yamanaka S (2009) Induced pluripotent
stem cells and reprogramming: seeing the science through the hype. Nat. Rev.
Genet. 10, 878–883.
Ben-David U, Benvenisty N (2011) The tumorigenicity of human embryonic and
induced pluripotent stem cells. Nat. Rev. Cancer 11, 268–277.
Blum B, Benvenisty N (2008) The tumorigenicity of human embryonic stem cells.
Adv. Cancer Res. 100, 133–158.
Blum B, Benvenisty N (2009) The tumorigenicity of diploid and aneuploid human
pluripotent stem cells. Cell Cycle 8, 3822–3830.
Blum B, Bar-Nur O, Golan-Lev T, Benvenisty N (2009) The anti-apoptotic gene
surviving contributes to teratoma formation by human embryonic stem cells.
Nat. Biotechnol. 27, 281–287.
Brown CJ, Lain S, Verma CS, Fersht AR, lane DP (2009) Awakening guardian
angels: drugging the p53 pathway. Nat. Rev. Cancer 9, 862–873.
Collado M, Serrano M (2006) The power and the promise of oncogene-induced
senescence markers. Nat. Rev. Cancer 6, 472–476.
Darabi R, Gehlbach K, Bachoo RM, Kamath S, Osawa M, Kamm KE, Kyba M,
Perlingeiro RC (2008) Functional skeletal muscle regeneration from differenti-
ating embryonic stem cells. Nat. Med. 14, 134–143.
Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display
of genome-wide expression patterns. Proc. Natl. Acad. Sci. U S A 95, 14863–
14868.
Ellis J, Baum C, Benvenisty N, Mostoslavasky G, Okano H, Stanford WL, Porteus
M, Sadelain M (2010) Benefits of utilizing gene-modified iPSCs for clinical
applications. Cell Stem Cell 7, 429–430.
Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM,
Weill JC, Blasco MA, Serrano M (2002) ‘‘Super p53’’ mice exhibit enhanced
DNA damage response, are tumor resistant and age normally. EMBO J. 21,
6225–6235.
Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I,
Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N,
Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisua Belmonte JC,
Safer iPS by enhancement of tumor suppressors, S. Menendez et al.
ª 2011 The Authors
Aging Cell ª 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland
49
Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, Zhang K (2011)
Somatic coding mutations in human induced pluripotent stem cells. Nature
471, 63–67.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ
(1996) Hypoxia-mediated selection of cells with diminished apoptotic potential
in solid tumours. Nature 379, 88–91.
Greaves MF (2006) Cord blood donor cell leukemia in recipients. Leukemia 20,
1633–1634.
Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Na¨rva¨ E, Ng S, Sourour
M, Ha¨ma¨la¨inen R, Olsson C, Lundin K, Mikkola M, Trokovic R, Peitz M, Bru¨stle
O, Bazett-Jones DP, Alitalo K, Lahesmaa R, Nagy A, Otonkoski T (2011) Copy
number variation and selection during reprogramming to pluripotency. Nature
471, 58–62.
Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM,
Belmonte JC (2009) Linking the p53 tumour suppressor pathway to somatic
cell reprogramming. Nature 460, 1140–1144.
Kiuru M, Boyer JL, O’Connor TP, Crystal RG (2009) Genetic control of wayward
pluripotent stem cells and their progeny after transplantation. Cell Stem Cell
4, 289–300.
Lane D, Levine A (2010) P53 research: the past thirty years and the next thirty
years. Cold Spring Harb. Perspect. Biol. 2, a000893.
Lawrenz B, Schiller H, Willbold E, Ruediger M, Muhs A, Esser S (2004) Highly
sensitive biosafety model for stem-cell-derived grafts. Cytotherapy 6, 212–222.
Li Z, Huang H, Boland P, Dominguez MG, Burfeind P, Lai KM, Lin HC, Gale NW,
Daly C, Auerbach W, Valenzuela D, Yancopoulos GD, Thurston G (2009)
Embryonic stem cell tumor model reveals role of vascular endothelial receptor
tyrosine phosphatase in regulating Tie2 pathway in tumor angiogenesis. Proc.
Natl. Acad. Sci. U S A 106, 22399–22404.
Liu GH, Barkho BZ, Ruiz S, Diep D, Qu J, Yang SL, Panopoulos AD, Suzuki K,
Kurian L, Walsh C, Thompson J, Boue S, Fung HL, Sancho-Martinez I, Zhang
K, Yates III J, Izpisua Belmonte JC (2011) Recapitulation of premature ageing
with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472, 221–225.
Maddocks OD, Vousden KH (2011) Metabolic regulation by p53. J. Mol. Med.
89, 237–245.
Matheu A, Pantoja C, Efeyan A, Criado LM, Martı´n-Caballero J, Flores JM, Klatt
P, Serrano M (2004) Increased gene dosage of Ink4a ⁄ Arf results in cancer
resistance and normal aging. Genes Dev. 18, 2736–2746.
Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, Plath K, Lowry
WE, Benvenisty N (2010) Identification and classification of chromosomal aber-
rations in human induced pluripotent stem cells. Cell Stem Cell 7, 521–531.
Menendez S, Goh AM, Camus S, Ng KW, Kua N, Badal V, Lane DP (2011)
MDM4 downregulates p53 transcriptional activity and response to stress dur-
ing differentiation. Cell cycle 10, 1100–1108.
Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyan-
agi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S (2009)
Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol.
27, 743–745.
Mizuno Y, Chang H, Umeda K, Niwa A, Iwasa T, Awaya T, Fukada S, Yamamoto
H, Yamanaka S, Nakahata T, Heike T (2010) Generation of skeletal muscle
stem ⁄ progenitor cells from murine induced pluripotent stem cells. FASEB J.
24, 2245–2253.
Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S (2010) Promotion
of direct reprogramming by transformation-deficient Myc. Proc. Natl. Acad.
Sci. U S A 107, 14152–14157.
Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent
induced pluripotent stem cells. Nature 448, 313–317.
Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ,
Consiglio A, Castella` M, Rı´o P, Sleep E, Gonza´lez F, Tiscornia G, Garreta E,
Aasen T, Veiga A, Verma IM, Surralle´s J, Bueren J, Izpisu´a Belmonte JC (2009)
Disease-corrected haematopoietic progenitors from Fanconi anaemia induced
pluripotent stem cells. Nature 460, 53–59.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S
(2007) Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 131, 861–872.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS,
Jones JM (1998) Embryonic stem cell lines derived from human blastocysts.
Science 282, 1145–1147.
Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X,
Soron G, Cooper B, Brayton C, Hee Park S, Thompson T, Karsenty G, Bradley
A, Donehower LA (2002) p53 mutant mice that display early ageing-associated
phenotypes. Nature 415, 45–53.
Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53
pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979–987.
Supporting Information
Additional supporting information may be found in the online version of
this article:
Fig. S1 Immunostaining of iPS clones for pluripotency markers.
Fig. S2 Quantitative PCR of silenced reprogramming factors.
Fig. S3 Differentiation of iPS lines to 3 germ-layers (in vitro).
Fig. S4 Differentiation of iPS lines to 3 germ-layers (in vivo).
Fig. S5 iPS lines display normal karyotype.
Fig. S6 Hierarchical clustering of iPS and ES lines.
Fig. S7 Quantitative PCR supporting microarray data.
Fig. S8 Raw data from long-term teratoma assay.
Fig. S9 Short-term teratoma assay tumour weights and images.
Fig. S10 Oct4 staining for EC component of teratomas.
Fig. S11 antibody staining for p53, p21cip, p19ARF and p16INK4a proteins
in teratocarcinomas.
Fig. S12 Quantitative PCR of differentiation and pluripotency markers fol-
lowing non-lineage directed differentiation of iPS lines.
Fig. S13 Differential induction of p53 target genes in iPS lines following
drug treatment.
Fig. S14 Transgenic F1 mice with increased tumour suppressor dosage are
protected from tumour development.
Data S1 Experimental procedures.
As a service to our authors and readers, this journal provides supporting
information supplied by the authors. Such materials are peer-reviewed and
may be re-organized for online delivery, but are not copy-edited or typeset.
Technical support issues arising from supporting information (other than
missing files) should be addressed to the authors.
Safer iPS by enhancement of tumor suppressors, S. Menendez et al.
ª 2011 The Authors
Aging Cell ª 2011 Blackwell Publishing Ltd/Anatomical Society of Great Britain and Ireland
50
